August 16, 2026 04:11 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
After SC rebuke, BCI chief apologises to NALSAR students over enrolment freeze row | Independence Day: PM Modi’s big youth pitch— AI training, free coaching amid exam row and job concerns | ‘Shakti Ki Saptadhara’: Modi reveals 7 pillars to power India’s next leap in his I-Day speech from Red Fort | West Bengal STF arrests 3 more suspected Pakistani spies in Cooch Behar | Bengal man arrested in Bengaluru over terror links, Afghanistan travel plan | Ajit Doval breaks silence on Operation Sindoor in Discovery’s explosive new docuseries | Rahul Gandhi's 'mock hug' taunt sparks row; Centre stresses 'mutual respect' with Italy | Delhi on high alert: Bomb threat to High Court, airport and multiple locations ahead of I-Day | ‘Who are they to interfere?’: CJI Surya Kant slams Bar Council of India over NALSAR students’ enrolment row | 'Shows how low Congress has sunk': BJP slams Rahul Gandhi over Modi foreign policy jibe

WHO set to resume hydroxychloroquine trial to fight Coronavirus outbreak

| @indiablooms | Jun 04, 2020, at 08:57 am

Geneva: Investigations will continue into the effectiveness of hydroxychloroquine in treating COVID-19,  , WHO chief Tedros Adhanom Ghebreyesus  said.

The drug, which is used to treat rheumatology conditions, was among four medicines being tested in a Solidarity Clinical Trial conducted by WHO and partners.

The Executive Group for the trial, representing 10 participating countries, put hydroxychloroquine on pause due to safety concerns. A monitoring committee has been reviewing related data.

“On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol”, said Tedros.

“The Executive Group received this recommendation and endorsed the continuation of all arms of the Solidarity Trial, including hydroxychloroquine.”

The Solidarity Clinical Trial was announced on 18 March: one week after the pandemic was declared, and 60 days after China shared the genetic sequence of the new coronavirus.

So far, more than 3,500 patients in 35 countries have been recruited.

The other treatments under study are remdesivir, previously tested as an Ebola treatment; lopinavir/ritonavir, which is a licensed treatment for HIV; and interferon beta-1a, a medicine for multiple sclerosis.

Support builds for ‘a people’s vaccine’

Relatedly, the UN and the International Red Cross and Red Crescent Movement on Wednesday called for governments and the private sector to unite towards developing “a people’s vaccine” against COVID-19.

They stressed that “no one should be left behind” in the race to identify the most effective means to defeat the virus.

“A people’s vaccine should protect the affluent in cities and the poor in rural communities, the old in care homes and the young in refugee camps”, they said.

“A global social contract for a people’s vaccine against COVID-19 is a moral imperative that brings us all together in our shared humanity.”

The partners said unity and commitment towards this common goal should also spark global resolve to sustain immunization against preventable diseases.

As UN agencies have reported, the COVID-19 pandemic has forced many countries to suspend or curtail routine childhood immunization programmes, putting some 80 million young lives at risk.

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.